Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947711 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects
A Phase 1 study, sponsored by Eisai Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02947711: Completed Phase 1 study, sponsored by Eisai Co..
NCT02947711 is a Phase 1 study that has completed, run by Eisai Co.. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02947711, a Phase 1 study, has completed, sponsored by Eisai Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This Phase 1, open-label, single-sequence, drug-drug Interaction study is conducted to evaluate the effect of diltiazem extended release (ER) (a moderate CYP3A inhibitor and P glycoprotein \[Pgp\] inhibitor) on the pharmacokinetics (PK) of a single oral dose of E2027 in healthy participants.
Interventions
- DRUG E2027
- DRUG Diltiazem ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-10 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
What the finished NCT02947711 record still lists
NCT02947711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which E2027 is the first listed.
NCT02947711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02947711 about?
NCT02947711 is a clinical study titled "Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects". This Phase 1, open-label, single-sequence, drug-drug Interaction study is conducted to evaluate the effect of diltiazem extended release (ER) (a moderate CYP3A inhibitor and P glycoprotein \[Pgp\] inhibitor) on the pharmacokinetics (PK) of a single oral dose of E2027 in healthy participants.
What is the current status of trial NCT02947711?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-10. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02947711?
The interventions under investigation include: E2027 (DRUG), Diltiazem ER (DRUG).
Who is sponsoring clinical trial NCT02947711?
This trial is sponsored by Eisai Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02947711's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia